Prescriber Checklist Tool

Remdesivir (Veklury)®

UTAH DEPARTMENT OF HEALTH

Updated 1/27/2022

Patient eligibility

The FDA approval of remdesivir (Veklury) has been expanded to include the indication for **treatment** of COVID-19 in the following individuals:

- ❑ Testing positive for SARS-CoV-2, and
- ❑ Aged ≥12 years and weighing at least 40 kg, and
- ❑ Having symptoms consistent with mild to moderate COVID-19, and
- ❑ Having symptom onset within 7 days, and
- ❑ At high risk for progression to severe COVID-19*, and
- ❑ Not hospitalized due to COVID-19.

Information before administration

Information to review prior to a patient receiving remdesivir

- ❑ Remdesivir should only be administered in settings in which healthcare providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS) as necessary.
- ❑ Specific dosing for eligible patients with mild to moderate COVID-19 and at high risk for progression to severe disease is 200 mg IV once daily for day 1 followed by 100 mg once daily for 2 days (for a total of 3 days of intravenously administered therapy).
- ❑ Determine eGFR in all patients before starting remdesivir, and monitor during treatment as clinically appropriate.
  - No dose adjustment in patients with eGFR ≥30 ml/min.
  - Remdesivir is not recommended in patients with eGFR <30 ml/min.
- ❑ Perform hepatic laboratory testing before starting remdesivir and monitor during treatment as clinically appropriate.
  - Consider discontinuing remdesivir if ALT increases to >10 times the upper limit of normal.
  - Discontinue remdesivir if ALT elevation is accompanied by signs or symptoms of liver inflammation.
- ❑ Determine prothrombin time in all patients before starting remdesivir and monitor during treatment as clinically appropriate.
- ❑ Risk of reduced antiviral activity of remdesivir when coadministered with chloroquine phosphate or hydroxychloroquine sulfate.
- ❑ Advise pregnant and recently pregnant individuals to visit https://covid-pr.pregistry.com to enroll or call 1-800-616-3791 to obtain more information about a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to remdesivir during pregnancy.
- ❑ Monitor patients during infusion and observe patients for at least 1 hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate.

Important notice

To report suspected adverse reactions, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

*Risk factors for progression to hospitalization include: age ≥60 years, hypertension, cardiovascular or cerebrovascular disease, diabetes mellitus, obesity (BMI of ≥30), immune compromise, chronic mild or moderate kidney disease, chronic liver disease, chronic lung disease, current cancer, or sickle cell disease.